Research
Hormonal
Multidisciplinary therapy reduces inflammatory biomarkers (CRP, IL-6, TNF-alpha) and improves the leptin/adiponectin ratio in adults with obesity.
Reducing inflammation is a key benefit of weight loss therapy. By losing weight through a multidisciplinary approach, you can lower levels of inflammatory markers like CRP and IL-6, and improve the balance of hormones like leptin and adiponectin, which protects against cardiovascular disease and other complications.
GoodSupportsHIGH confidence
Multidisciplinary therapy promoted clinical control in some proinflammatory adipokines and biomarkers of cardiometabolic risks, such as... Il- 6, PAI- 1, leptin, CRP, ICAM- 1, VCAM- 1, and tumor necrosis factor receptor 1
Why this rating
Based on narrative review of clinical studies showing reductions in specific biomarkers.
Source
Multidisciplinary Therapy to Target Obesity and Its Complications in Adult Population: A Narrative Review
Ana Raimunda Dâmaso et al. · Obesity Reviews · 2026
DOI 10.1111/obr.70093
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Multidisciplinary therapy combining nutritional, physical, and behavioral interventions reduces body weight, fat mass, and cardiometabolic risk factors in adults with obesity.Good
- Bariatric surgery results in greater weight loss and improvement in cardiac troponins compared to intensive lifestyle intervention alone in patients with severe obesity.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →